Skip to main content

Breast Cancer

HOPA Highlights, Breast Cancer

Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?

Meg Barbor, MPH

Meg Barbor, MPH

HOPA Abstracts, Breast Cancer, CDK4/6 Inhibitors

Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors

Abstract #CR04

HOPA Abstracts, Breast Cancer

Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers

Abstract #LB04

Case Reports, Breast Cancer, Adverse Events

Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report

Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP

Blake T. Robbins, PharmD, MBA; Alexander M. Kreimer, PharmD, BCPS; Reema A. Patel, MD; Allison R. Butts, PharmD, BCOP

Clinical Trials, Breast Cancer

Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice

Breast Cancer

A Subanalysis of the Phase 3 MONARCH 3 Study of Abemaciclib as Initial Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR-Positive, HER2-Negative, PIK3CA Mutation–Positive Breast Cancer

Breast Cancer

Updates on Endocrine Therapy for Metastatic Breast Cancer

Breast Cancer

Patient-Reported Outcomes from a Phase 3 Trial in Premenopausal Patients with ER-Positive, HER2-Negative, Lymph Node–Positive Breast Cancer

Breast Cancer

Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer

Page 3 of 12
Results 21 - 30 of 115